DV
Dividend Vision

PTGX — Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc. (PTGX)

Total return is 1225.6% over the past 10 years, 908.8 points ahead of SPY at 316.8%. Its deepest 1-year drawdown was 16.4%.

PTGX is a single-stock holding in Protagonist Therapeutics Inc., a biopharmaceutical company, rather than a diversified ETF. As an equity security without a stated dividend distribution policy, it generates no current yield and carries the concentrated risk associated with an individual stock investment. This holding appeals primarily to growth-oriented investors seeking exposure to the therapeutic development sector, rather than to income-focused dividend investors.

PTGX key facts

Asset type
Stock
Asset class
Equity
Inception date
08/11/2016
Distribution frequency
None
Last close
$155.10
Market cap
$10,036,255,744
Average volume
426300.0
Beta
1.794
Payout ratio
0.0
P/E ratio
146.3208
Forward P/E
37.4532
EPS
$1.06